Unlikely to cause harm — often a labeling or packaging issue.
Out-of-specification organic impurity results obtained during routine stability testing.
| Brand name | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE |
| Generic name | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | CANDESARTAN CILEXETIL, HYDROCHLOROTHIAZIDE |
| Distributed by / for | Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A |
| NDC | 0378-3002-77 |
| Full product label | Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. |
| Recalling firm | Mylan Pharmaceuticals Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 10,695 bottles |
| Recall initiated | 2020-10-02 |
| Report date | 2020-10-28 |
| Recall completed | 2022-01-24 |
| Recall number | D-0049-2021 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Morgantown WV United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗